Comparative minimum inhibitory and mutant prevention drug concentrations of enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin against bovine clinical isolates of Mannheimia haemolytica.
Mannheimia haemolytica is the most prevalent cause of bovine respiratory disease (BRD) and this disease accounts for 75% of morbidity, 50-70% of feedlot deaths and is estimated to cost up to $1 billion dollars annually in the USA. Antimicrobial therapy is essential for reducing morbidity, mortality and impacting on the financial burden of this disease. Due to the concern of increasing antimicrobial resistance, investigation of antibacterial agents for their potential for selecting for resistance is of paramount importance. A novel in vitro measurement called the mutant prevention concentration (MPC) defines the antimicrobial drug concentration necessary to block the growth of the least susceptible cells present in high density (≥10(7) colony forming units/ml) bacterial populations such as those seen in acute infection. We compared the minimum inhibitory concentration (MIC) and MPC values for 5 antimicrobial agents (ceftiofur, enrofloxacin, florfenicol, tilmicosin, tulathromycin) against 285 M. haemolytica clinical isolates. The MIC(90)/MPC(90) values for each agent respectively were as follows: 0.016/2, 0.125/1, 2/≥16, 8/≥32, 2/8. Dosing to achieve MPC concentrations (where possible) may serve to reduce the selection of bacterial subpopulations with reduced antimicrobial susceptibility. The rank order of potency based on MIC(90) values was ceftiofur > enrofloxacin > florfenicol = tulathromycin > tilmicosin. The rank order of potency based on MPC(90) values was enrofloxacin > ceftiofur > tulathromycin > florfenicol ≥ tilmicosin.
Department of Clinical Microbiology, Royal University Hospital and the Saskatoon Health Region, Departments of Microbiology and Immunology, Pathology and Ophthalmology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada. joseph.blondeau@saskatoonhealthregion.ca
J M
JM
Blondeau
S
S
Borsos
L D
LD
Blondeau
B J J
BJ
Blondeau
C E
CE
Hesje
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002417:Cattle; D002418:Cattle Diseases / Q000382:microbiology*; D002511:Cephalosporins / Q000494:pharmacology; D004187:Disaccharides / Q000494:pharmacology; D024901:Drug Resistance, Multiple, Bacterial; D000077422:Enrofloxacin; D024841:Fluoroquinolones / Q000494:pharmacology; D006571:Heterocyclic Compounds / Q000494:pharmacology; D016978:Mannheimia haemolytica / Q000187:drug effects* / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D013839:Thiamphenicol / Q000031:analogs & derivatives / Q000494:pharmacology; D015645:Tylosin / Q000031:analogs & derivatives / Q000494:pharmacology; D014481:United States; D018942:Macrolides
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D004187:Disaccharides; D000077422:Enrofloxacin; D024841:Fluoroquinolones; D006571:Heterocyclic Compounds; D013839:Thiamphenicol; D015645:Tylosin; C053503:ceftiofur; C035534:florfenicol; C485204:tulathromycin; D018942:Macrolides; C052319:tilmicosin